Disclosed is the use of a cholesterol-reduced ruminant dairy product in the manufacture of a medicament for use in the treatment and/or the prevention of one or more conditions selected from cardiovascular disease, inflammatory disease, neurological disease, liver disease, or for decreasing the atherogenic ratio, or for increasing the poly-unsaturated fatty acids content in a mammal&rsquo；s blood, or for decreasing the triglyceride content in a mammal&rsquo；s blood, wherein the cholesterol content of the medicament is comprised between 10 mg/100g fat and 150 mg/100g fat.
